Patents

Oragenics Obtains U.S. Patent for IVIAT

October 17, 2011

Oragenics, Inc., Tampa, FL, has been issued patent No. 8,034,571 from the U.S. Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT). This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism, which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies.

blog comments powered by Disqus